“We are focused on developing Tiprelestat as a disease modifying therapy for patients with Pulmonary Arterial Hypertension, a highly debilitating and rapidly progressive rare disease.”
Natural protection smart reinvented Discover the gamechanger in the treatment of pulmonary-arterial hypertension and in the prevention of postoperative inflammatory complications: our investigational medical product Tiprelestat. Read now all you need to know about the pioneering anti-inflammatory and tissue protective drug being developed by tiakis BIOTECH AG.
Read all about our goal to shift the paradigm toward a preventive and underlying cause focused approach for patients and why we believe in strong values like: